Lana Ilic Prelogovic, Gorana Perina Lakoš and Marina Krstanovic examine the availability of information that generics companies need to develop their products. The development of generic pharmaceuticals requires a comprehensive approach in terms of the analysis of data relating to the relevant reference product or products...
Please login to read the full article.
Scrip Regulatory Affairs
A Review of Regulatory Authority Databases in Central and Eastern Europe for the Purposes of Generic Pharmaceutical Development
27 October 2009
Lana Ilic Prelogovic, Gorana Perina Lakoš and Marina Krstanovic
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Industry and European Commission tackle barriers to biosimilars market penetration
- Supreme Court takes another stab at refining US patent law
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
